MarketPulse

roluperidone

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Minerva Neurosciences to Present CNS Pipeline at Stifel Forum Ahead of Key Phase 3 Trial

Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.
NERVbiopharmaceuticalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Minerva Neurosciences, Inc.

Minerva Neurosciences Posts $293M Loss But Bolsters Cash Reserves for Schizophrenia Drug Trial

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.
NERVprivate placementPhase 3 trial